Use data of all dosed subjects [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-09-19 15:16  – Posting: # 20617
Views: 2,136

Hi Elena,

» […] What combined data should be evaluated after stage 2 completion: ONLY for Cmax or for Cmax and AUCt?

Whatever drives the second stage, you have to use all data (Cmax and AUC). Whilst from a statistical perspective there would be no need to assess AUC (already BE in the first stage) no regulator would accept that. Once you dosed subjects, you have to use the data. No way out.

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,345 posts in 4,273 threads, 1,402 registered users;
online 14 (0 registered, 14 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 19:42 CET

No one wants to learn from mistakes, but we cannot learn enough
from successes to go beyond the state of the art.    Henry Petroski

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5